Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|September 30, 2024

Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging

Author(s)Félix Guerrero-Ramos, MD, PhD, FEBU , Srikala Sridhar, MD , Jens Bedke, MD

Key Takeaways

NMIBC is defined by tumors not invading the bladder muscle layer, with symptoms like hematuria and dysuria.
Diagnostic confirmation involves cystoscopy, urine cytology, and imaging studies.
The economic burden of NMIBC is substantial due to ongoing surveillance and treatment expenses.
Smoking and occupational exposures are primary risk factors, with no definitive genetic links identified.
Accurate staging is essential for effective treatment, as misclassification can adversely affect patient management.

SHOW MORE

Panelists discuss how non–muscle-invasive bladder cancer (NMIBC) presents with specific symptoms and diagnostic procedures, emphasize the significant economic burden on health care systems, and highlight key risk factors like smoking and occupational exposure while also addressing the critical importance of accurate staging for guiding treatment decisions and the potential consequences of incorrect staging on patient outcomes.

Episodes in this series

EP. 1 Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging

EP. 1 Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging

EP. 2 NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

EP. 2 NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

EP. 3 Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC

EP. 3 Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC

EP. 4 Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

EP. 4 Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

EP. 5 Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC

EP. 5 Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC

EP. 6 Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy

EP. 6 Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy

EP. 7 Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC

EP. 7 Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC

EP. 8 Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management

EP. 8 Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management

EP. 9 Exploring Emerging Data in NMIBC

EP. 9 Exploring Emerging Data in NMIBC

EP. 10 Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC

EP. 10 Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC

Video content above is prompted by the following:

What is non–muscle-invasive bladder cancer (NMIBC)?
What are the common symptoms and signs of NMIBC?
What diagnostic procedures are typically used to confirm a case of NMIBC?
What is the economic burden of this disease for health care systems and insurance companies?

What are the main risk factors associated with the development of NMIBC? Grabe-Heyne 2023
Smoking as a risk factor for the development of bladder cancer
Occupational risk factors
No clear genetic association (that we know of so far)

What are the different stages and grades of NMIBC?Grabe-Heyne 2023
What is the importance of getting the stage correct? (PMID 38994181)
Ensuring appropriate treatment based on patient stage
How often do you feel that patients are incorrectly staged? How does that then affect the patient treatment journey?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Surabhi Amar, MD, MHA, MBBS; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures

Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC

Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study

BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC

Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer

© 2025 MJH Life Sciences^®

All rights reserved.